Dominique C. van Rappard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dominique C. van Rappard has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Jan R. Mekkes
Department of Dermatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands
5 shared publicationsJ.R. Mekkes
Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
4 shared publicationsJ.E. Mooij
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
2 shared publications- Allard C. van der Wal
Amsterdam UMC, Academic Medical Center, Amsterdam, the Netherlands; Maastricht University Medical Center (MUMC), Maastricht, the Netherlands
1 shared publication D.L.P. Baeten
Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
1 shared publication- Jacqueline Limpens
Medical Library, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- 1 January 2016
- Published by Elsevier in Dermatologic Clinics
- Vol. 34 (1) , 69-80
Randomized Controlled Trials for the Treatment of Hidradenitis Suppurativa
- 1 January 2016
- Published by Elsevier in Dermatologic Clinics
- Vol. 34 (1) , 69-80
Randomized Controlled Trials for the Treatment of Hidradenitis Suppurativa
- 21 September 2015
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (10) , e104-e106
Four cases of plaque form hidradenitis suppurativa
- 21 September 2015
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (10) , e104-e106
Four cases of plaque form hidradenitis suppurativa
- 14 March 2013
- Published by Wiley in International Journal of Dermatology
- Vol. 53 (1) , e77-e79
Hidradenitis suppurativa not associated withCARD15/NOD2mutation: a case series
- 14 March 2013
- Published by Wiley in International Journal of Dermatology
- Vol. 53 (1) , e77-e79
Hidradenitis suppurativa not associated withCARD15/NOD2mutation: a case series
- 18 April 2012
- Published by Wiley in International Journal of Dermatology
- Vol. 52 (11) , 1418-1420
Six patients with pyoderma gangrenosum successfully treated with infliximab
- 18 April 2012
- Published by Wiley in International Journal of Dermatology
- Vol. 52 (11) , 1418-1420
Six patients with pyoderma gangrenosum successfully treated with infliximab
- 12 April 2012
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 24 (5) , 392-404
The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review
To provide an overview of the current evidence regarding off-label treatment of hidradenitis suppurativa (HS) with TNF-α inhibitors, a systematic search was performed in MEDLINE, EMBASE and CENTRAL. Any type of original article concerning HS patients treated with infliximab, etanercept and/or adalimumab was included. No language restriction was applied. After full-text screening 65 studies involving 459 patients met the inclusion criteria and were subjected to data extraction. Four randomized controlled trials (RCTs) were available, and the remainders were case series or reports. Only RTCs were subjected to methodological quality assessment. Based on efficacy data extracted from the case reports, a moderate to good response was seen in 82% of the patients treated with infliximab, 76% of the patients treated with adalimumab, and 68% of the patients treated with etanercept. Due to the moderate level of evidence only a weak recommendation can be provided. If conventional treatment options fail, the use of TNF-α inhibitors can be a useful supplement for the treatment of recurrent severe HS. Infliximab should be preferred based on the most encouraging results regarding efficacy and expenses. Also adalimumab seems promising when administered in higher doses. The use of etanercept should be discouraged.
- 12 April 2012
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 24 (5) , 392-404
The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review
To provide an overview of the current evidence regarding off-label treatment of hidradenitis suppurativa (HS) with TNF-α inhibitors, a systematic search was performed in MEDLINE, EMBASE and CENTRAL. Any type of original article concerning HS patients treated with infliximab, etanercept and/or adalimumab was included. No language restriction was applied. After full-text screening 65 studies involving 459 patients met the inclusion criteria and were subjected to data extraction. Four randomized controlled trials (RCTs) were available, and the remainders were case series or reports. Only RTCs were subjected to methodological quality assessment. Based on efficacy data extracted from the case reports, a moderate to good response was seen in 82% of the patients treated with infliximab, 76% of the patients treated with adalimumab, and 68% of the patients treated with etanercept. Due to the moderate level of evidence only a weak recommendation can be provided. If conventional treatment options fail, the use of TNF-α inhibitors can be a useful supplement for the treatment of recurrent severe HS. Infliximab should be preferred based on the most encouraging results regarding efficacy and expenses. Also adalimumab seems promising when administered in higher doses. The use of etanercept should be discouraged.
- 9 January 2012
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 167 (1) , 206-208
Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions
- 9 January 2012
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 167 (1) , 206-208
Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions
- 1 January 2012
- Vol. 156 (17) , A2845
[A woman with periocular swelling].
We present a 37-year-old woman with an 8-year history of rosacea, who developed persistent swelling of the right lower eyelid, diagnosed as Morbihan's disease. Morbihan's disease is considered a rare complication of rosacea.
- 1 January 2012
- Vol. 156 (17) , A2845
[A woman with periocular swelling].
We present a 37-year-old woman with an 8-year history of rosacea, who developed persistent swelling of the right lower eyelid, diagnosed as Morbihan's disease. Morbihan's disease is considered a rare complication of rosacea.
- 3 August 2011
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 26 (7) , 898-902
Mild to moderate hidradenitis suppurativa treated with local excision and primary closure
Background Hidradenitis suppurativa (HS) is a chronic skin disease with a great impact on quality of life. Treatment with antibiotics or anti‐inflammatory drugs, such as prednisone or TNF‐alpha‐inhibitors usually achieves only temporary improvement. Surgical intervention is considered as the only curative treatment for recurrent lesions.Objective To determine the efficacy and patient satisfaction of local excision followed by primary closure.Methods Between 2005 and 2010, 92 local excisions with primary closure were performed in 57 patients with mild to moderate HS. All patients were treated on an outpatient basis, under local anaesthesia. Local excision was defined as complete excision of the affected tissue, beyond the borders of activity, leaving clear margins. The medical records were reviewed retrospectively in 2010. The final outcome of the procedure, cosmetic appearance and patient satisfaction was measured using a questionnaire.Results Successful treatment, without recurrence, was accomplished in 66% of the cases. The intervention was generally well tolerated: 84% of the patients stated that they would undergo the same surgical procedure again if necessary, and 89% would recommend the procedure to other patients.Conclusion Local excision followed by primary closure is a valuable treatment for patients with mild to moderate HS (Hurly stage I & II), with low morbidity and a high patient satisfaction rate.
- 3 August 2011
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 26 (7) , 898-902
Mild to moderate hidradenitis suppurativa treated with local excision and primary closure
Background Hidradenitis suppurativa (HS) is a chronic skin disease with a great impact on quality of life. Treatment with antibiotics or anti‐inflammatory drugs, such as prednisone or TNF‐alpha‐inhibitors usually achieves only temporary improvement. Surgical intervention is considered as the only curative treatment for recurrent lesions.Objective To determine the efficacy and patient satisfaction of local excision followed by primary closure.Methods Between 2005 and 2010, 92 local excisions with primary closure were performed in 57 patients with mild to moderate HS. All patients were treated on an outpatient basis, under local anaesthesia. Local excision was defined as complete excision of the affected tissue, beyond the borders of activity, leaving clear margins. The medical records were reviewed retrospectively in 2010. The final outcome of the procedure, cosmetic appearance and patient satisfaction was measured using a questionnaire.Results Successful treatment, without recurrence, was accomplished in 66% of the cases. The intervention was generally well tolerated: 84% of the patients stated that they would undergo the same surgical procedure again if necessary, and 89% would recommend the procedure to other patients.Conclusion Local excision followed by primary closure is a valuable treatment for patients with mild to moderate HS (Hurly stage I & II), with low morbidity and a high patient satisfaction rate.
- 14 July 2011
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 23 (4) , 284-289
Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa
Background: Hidradenitis suppurativa (HS) is a chronic relapsing skin disease. Recent studies have shown promising results of anti-tumor necrosis factor-alpha treatment. Objective: To compare the efficacy and safety of infliximab and adalimumab in the treatment of HS. Methods: A retrospective study was performed to compare 2 cohorts of 10 adult patients suffering from severe, recalcitrant HS. In 2005, 10 patients were treated with infliximab intravenous (i.v.) (3 infusions of 5 mg/kg at weeks 0, 2, and 6). In 2009, 10 other patients were treated in the same hospital with adalimumab subcutaneous (s.c.) 40 mg every other week. Both cohorts were followed up for 1 year using identical evaluation methods [Sartorius score, quality of life index, reduction of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), patient and doctor global assessment, and duration of efficacy]. Results: Nineteen patients completed the study. In both groups, the severity of the HS diminished. Infliximab performed better in all aspects. The average Sartorius score was reduced to 54% of baseline for the infliximab group and 66% of baseline for the adalimumab group. Conclusions: Adalimumab s.c. 40 mg every other week is less effective than infliximab i.v. 5 mg/kg at weeks 0, 2, and 6.
- 14 July 2011
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 23 (4) , 284-289
Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa
Background: Hidradenitis suppurativa (HS) is a chronic relapsing skin disease. Recent studies have shown promising results of anti-tumor necrosis factor-alpha treatment. Objective: To compare the efficacy and safety of infliximab and adalimumab in the treatment of HS. Methods: A retrospective study was performed to compare 2 cohorts of 10 adult patients suffering from severe, recalcitrant HS. In 2005, 10 patients were treated with infliximab intravenous (i.v.) (3 infusions of 5 mg/kg at weeks 0, 2, and 6). In 2009, 10 other patients were treated in the same hospital with adalimumab subcutaneous (s.c.) 40 mg every other week. Both cohorts were followed up for 1 year using identical evaluation methods [Sartorius score, quality of life index, reduction of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), patient and doctor global assessment, and duration of efficacy]. Results: Nineteen patients completed the study. In both groups, the severity of the HS diminished. Infliximab performed better in all aspects. The average Sartorius score was reduced to 54% of baseline for the infliximab group and 66% of baseline for the adalimumab group. Conclusions: Adalimumab s.c. 40 mg every other week is less effective than infliximab i.v. 5 mg/kg at weeks 0, 2, and 6.
- 24 June 2011
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 165 (1) , 194-198
New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab
Hidradenitis suppurativa (HS) can be associated with several forms of arthritis, usually considered as reactive arthritis. A new observation is that some patients with HS develop arthritis after treatment with infliximab (antitumour necrosis factor-α). A retrospective study was performed to establish the frequency and clinical presentation of new-onset arthritis during infliximab treatment. Between 2005 and 2009, 27 individuals with severe HS were treated with infliximab and followed up closely. Laboratory parameters and side-effects were recorded. The frequency of arthritis was compared with control groups consisting of 227 patients with HS not treated with any biological, 22 patients with HS treated with adalimumab and 28 patients with psoriasis treated with infliximab, in the same period at the same clinic. Five of the 27 patients with HS (18%) treated with infliximab developed an acute and painful polyarthritis during treatment. The arthritis occurred on average after 12 months of treatment, was not clearly associated with anti-infliximab antibodies and resolved on average after 4 months. Interestingly, none of the patients had suffered from arthritis before despite the long duration of HS and all showed a good skin response to infliximab. Moreover, arthritis was not observed in any of the control groups. Compared with the adalimumab group and the psoriasis group, odds ratios of 7·241 [95% confidence interval (CI) 1·15-45·6] and 9·025 (95% CI 1·45-55·82) were calculated. The five cases described in this article suggest that infliximab treatment in HS can induce a transient but severe polyarthritis. The underlying mechanisms remain to be investigated further.
- 24 June 2011
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 165 (1) , 194-198
New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab
Hidradenitis suppurativa (HS) can be associated with several forms of arthritis, usually considered as reactive arthritis. A new observation is that some patients with HS develop arthritis after treatment with infliximab (antitumour necrosis factor-α). A retrospective study was performed to establish the frequency and clinical presentation of new-onset arthritis during infliximab treatment. Between 2005 and 2009, 27 individuals with severe HS were treated with infliximab and followed up closely. Laboratory parameters and side-effects were recorded. The frequency of arthritis was compared with control groups consisting of 227 patients with HS not treated with any biological, 22 patients with HS treated with adalimumab and 28 patients with psoriasis treated with infliximab, in the same period at the same clinic. Five of the 27 patients with HS (18%) treated with infliximab developed an acute and painful polyarthritis during treatment. The arthritis occurred on average after 12 months of treatment, was not clearly associated with anti-infliximab antibodies and resolved on average after 4 months. Interestingly, none of the patients had suffered from arthritis before despite the long duration of HS and all showed a good skin response to infliximab. Moreover, arthritis was not observed in any of the control groups. Compared with the adalimumab group and the psoriasis group, odds ratios of 7·241 [95% confidence interval (CI) 1·15-45·6] and 9·025 (95% CI 1·45-55·82) were calculated. The five cases described in this article suggest that infliximab treatment in HS can induce a transient but severe polyarthritis. The underlying mechanisms remain to be investigated further.